The CKMB UDR assay is an in vitro diagnostic test used for the kinetic quantitative determination on Unicel DxC 600 System of the CK-MB isoenzyme activity of creatine kinase in serum and Liheparin plasma by inhibition method. The assay is intended for professional use only. Creatine Kinase (CK) catalyses the reversible phosphorylation of creatine by ATP. CK is a dimer composed of two subunits which form three active isoenzymes: BB (CK-1), MB (CK-2), MM (CK-3). CK-BB isoenzyme only rarely appears in serum.

Elevated CK values are due to muscular damages and associated pathologies. CK determination, usually performed with CK2 (also called CK-MB), is used for the diagnosis and follow-up of AMI (acute myocardial infarction) and some muscular diseases.

Device Description

Anti CK-M mouse monoclonal antibodies in the reagent 1 inhibit the CK-M subunit in the sample without affecting the CK-B subunits. The CK-B activity is determined by the CK-NAC method and corresponds to half the CK-MB activity.

AI/ML Overview

The provided text describes the performance characteristics of the CKMB UDR Assay, focusing on its substantial equivalence to a predicate device. Here's a breakdown of the acceptance criteria and study details:

1. A table of acceptance criteria and the reported device performance

Acceptance Criteria (Implied)	Reported Device Performance
Method Comparison with Predicate Device:
High correlation coefficient (r) with predicate device	r = 0.999
Slope close to 1 with predicate device	Slope = 0.96
Small intercept value with predicate device	Intercept = 2.40 U/L
Imprecision (within-run and inter-assay):
Acceptable %CV values for various concentrations	20-day Inter-assay Imprecision:
	- Human sera pool #1 (Mean 10.7 U/L): Total Imprecision CV% = 4.2%, Within run CV% = 4.2%
	- Human sera pool #2 (Mean 19.0 U/L): Total Imprecision CV% = 2.6%, Within run CV% = 2.6%
	- Human sera pool #3 (Mean 25.4 U/L): Total Imprecision CV% = 2.0%, Within run CV% = 2.0%
	- Human sera pool #4 (Mean 33.4 U/L): Total Imprecision CV% = 3.6%, Within run CV% = 3.6%
	- Spiked Human sera pool (Mean 584.1 U/L): Total Imprecision CV% = 0.9%, Within run CV% = 0.6%
Analytical Measurement Range (AMR):
A defined and clinically relevant range of accurate measurement.	Found lower limit: 7.4 U/L; Found upper limit: 600.0 U/L. Claimed AMR: 9.0 to 600.0 U/L.

Study Proving Acceptance Criteria (Type of Study):

The study described is a comparative performance study to demonstrate substantial equivalence to a predicate device (Roche CK-MB assay K003158). This is primarily an analytical validation study.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Test Set Sample Size: 306 human sera samples (for method comparison).
Data Provenance: The text does not specify the country of origin. It implicitly describes a prospective study in the sense that samples were tested with both the new device and the predicate for comparison. However, the exact collection method (e.g., whether samples were collected specifically for this study or were existing banked samples) is not explicitly stated. It is referred to as "human sera samples," suggesting clinical samples.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This is not applicable to this type of analytical device validation. The "ground truth" for an assay like CKMB is established by the reference method (in this case, the predicate device) and the intrinsic chemical/biological properties being measured, not by expert consensus on interpretations.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. This is not a study involving human interpretation or adjudication of results. The comparison is quantitative between two analytical instruments.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is an in vitro diagnostic assay, not an imaging device or AI-assisted diagnostic tool that involves human readers.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Yes, the studies described are standalone (algorithm/assay only) performance assessments. The device measures CK-MB activity directly, and its performance is evaluated based on its analytical characteristics (correlation, precision, range) against a predicate device, without human intervention in the result determination.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The "ground truth" in this context is the results obtained from the legally marketed predicate device (Roche CK-MB assay K003158). The study aimed to demonstrate that the new device's measurements are substantially equivalent to those of the predicate device. For the imprecision and AMR studies, the ground truth is implicitly the inherent biological measurement of the samples at various concentrations using the new device.

8. The sample size for the training set

Not applicable. This is not a machine learning or AI-driven device that requires a training set in that sense. It is a chemical assay.

9. How the ground truth for the training set was established

Not applicable, as there is no training set for this type of device.

Summary

{0}------------------------------------------------

AUG 1 9 2011

510(k) Summary

K102706 Summary page 1 of 4

Name of Submitter and details	SENTINEL CH. SpA Via Robert Koch, 2 20152 Milan - Italy 39 02 34551448 Fax: 39 02 34551464
Contact Person	Fabio Rota Technical Director +39 02 34551448 Fax: +39 02 34551464
Date of Preparation of this Summary:	August 18th, 2011
Trade Name:	CKMB UDR Assay
Classification Name:	Creatine phosphokinase/creatine kinase or isoenzymes test system.
Device Classification product code Subsequent Product Code	JHW / JIX
Regulation number/Class	862.1215 / Class II

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is: __K102706.

Test Description:

{1}------------------------------------------------

K102706 Summary page 2 of 4

Substantial Equivalence:

The CKMB UDR assay is substantially equivalent to Roche CK-MB assay (K003158). Both assays yield similar Performance Characteristics.

Similarities: . Both assays are used for the quantitative determination of CKMB . Both assays are based on immunologic inhibition of the CK-M subunit of Human Creatine kinase . Both assays are based on the same Immunological key materials: anti CK-M mouse monoclonal antibodies, which are bought from Roche. . Both assays are based on the Kinetic measurement of the CK-B subunit of the human Creatine Kinase . Both assays do have 340 nm as main wavelength . Both assays utilize reagents in R1 and R2 Liquid format. Both assays are based on human Serum and Li-heparin ● Plasma. . Both assays yield similar clinical results.

Differences:

. The predicate device assay recommends the use of EDTA plasma specimens. Sentinel assay recommends the use of serum and Li-Heparin plasma only.

{2}------------------------------------------------

Intended Use:

Performance Characteristics:

Comparative performance studies were conducted using the UniCel DxC 600 Synchron System. Sentinel CKMB UDR assay on UniCel DxC 600 System yielded comparable performances to the Roche CK-MB (K003158) on Roche/Hitachi Modular P800 Analyzer (K953239/A5).

Method comparison

Sentinel CKMB UDR assay on UniCel DxC 600 System was compared to predicate device Roche CK-MB (K003158) on Roche/Hitachi Modular P800 by testing 306 human sera samples. This comparison showed a correlation coefficient (r) of 0.999, slope of 0.96, and intercept of 2.40 U/L.

Conclusions

The generated data demonstrated an acceptable correlation between the CKMB UDR assay on the UniCel DxC 600 System vs. the Roche CKMB (K003158) on Roche/Hitachi Modular P800 Analyzer.

Imprecision

Precision studies were conducted by using CKMB UDR on the UniCel DxC 600 System. The found %CV values for 20-day Inter-assay Imprecision were:

{3}------------------------------------------------

K102706 Summary page 4 of 4

	N	Mean(U/L)	Total Imprecision		Within run
			SD (U/L)	CV%	SD(U/L)	CV%
Human sera pool #1	40	10.7	0.45	4.2	0.45	4.2
Human sera pool #2	40	19.0	0.49	2.6	0.49	2.6
Human sera pool #3	40	25.4	0.50	2.0	0.50	2.0
Human sera pool #4	40	33.4	1.21	3.6	1.21	3.6
Spiked Human sera pool	40	584.1	5.11	0.9	3.76	0.6

Analytical Measurement Range (AMR)

The found lower limit of the AMR of CKMB UDR on the UniCel DxC 600 System was 7.4 U/L. The found upper limit of the AMR was 600.0 U/L. The claimed AMR will be 9.0 to 600.0 U/L.

Conclusions for 510(k) Summary

Method comparison, Imprecision and AMR data demonstrate that the analytical performance of the CKMB UDR on the UniCel DxC 600 Synchron System is substantially equivalent to Roche CK-MB (K003158) on the Roche/Hitachi Modular P800 Analyzer

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the text "DEPARTMENT OF HEALTH & HUMAN SERVICES". The text is in all caps and is in a serif font. The text is centered in the image and is the only element in the image. The text is likely the header of a document or website.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993

SENTINEL CH SpA c/o Fabio Rota Via Robert Koch 20152 Milan, Italy

Re: K102706

AUG 1 9 2011

Trade/Device Name: CKMB UDR Assay Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system. Regulatory Class: Class II Product Code: JHS Dated: August 10, 2011 Received: August 12, 2011

Dear Mr. Rota:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

{5}------------------------------------------------

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free no mber (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours.

C.C.

Courmey Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

: « » »

Enclosure

{6}------------------------------------------------

Indications for Use

510(k) Number (if known): K102706

Device Name: CKMB UDR

Indications for Use:

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Rute Chube

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) K102706

page 1 of 1

Regulation Number and Section

§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system.

(a)
Identification. A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.(b)
Classification. Class II.